PhilippeArmandMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Armand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Armand's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-2305

Fax+1 617-632-4422

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
University of California San Francisco School of MedicineClass of 2000

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2004 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation Start of enrollment: 2008 Aug 01
Terminated
Not Applicable
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Start of enrollment: 2009 Jun 01
Completed
Phase 3
Observational Study of Iron Overload in Stem Cell Transplantation Start of enrollment: 2008 Mar 01
Completed
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Start of enrollment: 2010 Jun 01
Completed
Phase 2
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma Start of enrollment: 2012 Aug 16
Active, not recruiting
Phase 2
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma Start of enrollment: 2013 Jul 01
Terminated
Phase 2
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) Start of enrollment: 2014 Mar 05
Completed
Phase 2
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) Start of enrollment: 2014 Mar 26
Completed
Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) Start of enrollment: 2014 Aug 12
Completed
Phase 2
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma Start of enrollment: 2023 Apr 06
Recruiting
Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma.
Katie Maurer, Isabella N Grabski, Roch Houot, Satyen H Gohil, Shogo Miura
Blood. 2024-12-12
A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
Journal of Clinical Oncology. 2024-12-07
A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treat...
Eric Jacobsen, Ashley Plant, Robert Redd, Philippe Armand, Mikaela McDonough
Leukemia & Lymphoma. 2024-12-01

Journal Articles

Mass Cytometry of Hodgkin Lymphoma Reveals a CD4+ Exhausted T-effector and T-regulatory Cell Rich Microenvironment
David Wu, Margaret A Shipp, Jonathan R Fromm, Philippe Armand, Scott J Rodig, Blood

Abstracts/Posters

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices
Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopo...
Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade
Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Optimizing Clinical Outcomes in Blood Cancers Through Groundbreaking Translational Research
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Role of Immune Checkpoint Blockade in the Treatment of Refractory/Relapsed Hodgkin and Non-Hodgkin Lymphoma
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Study Sounds Note of Caution on Effectiveness of Covid Vaccines for Patients with Lymphoid MalignanciesAugust 24th, 2021
MRD in NHL: New Technologies Poised to Redefine Tx ParadigmsAugust 7th, 2019
$Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma$
Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin LymphomaJuly 1st, 2019
Join now to see all